The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1

Jeffrey M. Jacobson, Steven E. Bosinger, Minhee Kang, Pablo Belaunzaran-Zamudio, Roy M. Matining, Cara C. Wilson, Charles Williams Flexner, Brian Clagett, Jill Plants, Sarah Read, Lynette Purdue, Laurie Myers, Linda Boone, Pablo Tebas, Princy Kumar, David Clifford, Daniel Douek, Guido Silvestri, Alan L. Landay, Michael M. Lederman

Research output: Contribution to journalArticle

Abstract

Immune activation associated with HIV-1 infection contributes to morbidity and mortality. We studied whether chloroquine, through Toll-like receptor (TLR) antagonist properties, could reduce immune activation thought to be driven by TLR ligands, such as gut-derived bacterial elements and HIV-1 RNAs. AIDS Clinical Trials Group A5258 was a randomized, double-blind, placebo-controlled study in 33 HIV-1-infected participants off antiretroviral therapy (ART) and 37 participants on ART. Study participants in each cohort were randomized 1:1 to receive chloroquine 250 mg orally for the first 12 weeks then cross over to placebo for 12 weeks or placebo first and then chloroquine. Combining the periods of chloroquine use in both arms of the on-ART cohort yielded a modest reduction in the proportions of CD8 T cells co-expressing CD38 and DR (median decrease = 3.0%, p = .003). The effect on immune activation in the off-ART cohort was likely confounded by increased plasma HIV-1 RNA during chloroquine administration (median 0.29 log10 increase, p <.001). Transcriptional analyses in the off-ART cohort showed decreased expression of interferon-stimulated genes in 5 of 10 chloroquine-treated participants and modest decreases in CD38 and CCR5 RNAs in all chloroquine-treated participants. Chloroquine modestly reduced immune activation in ART-treated HIV-infected participants. Clinical Trials Registry Number: NCT00819390.

Original languageEnglish (US)
Pages (from-to)636-647
Number of pages12
JournalAIDS Research and Human Retroviruses
Volume32
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Chloroquine
Interferon-gamma
HIV-1
Toll-Like Receptors
Placebos
RNA
Therapeutics
Clinical Trials
Interferons
HIV Infections
Registries
Acquired Immunodeficiency Syndrome
HIV
Ligands
Morbidity
T-Lymphocytes
Mortality
Genes

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Jacobson, J. M., Bosinger, S. E., Kang, M., Belaunzaran-Zamudio, P., Matining, R. M., Wilson, C. C., ... Lederman, M. M. (2016). The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. AIDS Research and Human Retroviruses, 32(7), 636-647. https://doi.org/10.1089/aid.2015.0336

The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. / Jacobson, Jeffrey M.; Bosinger, Steven E.; Kang, Minhee; Belaunzaran-Zamudio, Pablo; Matining, Roy M.; Wilson, Cara C.; Flexner, Charles Williams; Clagett, Brian; Plants, Jill; Read, Sarah; Purdue, Lynette; Myers, Laurie; Boone, Linda; Tebas, Pablo; Kumar, Princy; Clifford, David; Douek, Daniel; Silvestri, Guido; Landay, Alan L.; Lederman, Michael M.

In: AIDS Research and Human Retroviruses, Vol. 32, No. 7, 01.07.2016, p. 636-647.

Research output: Contribution to journalArticle

Jacobson, JM, Bosinger, SE, Kang, M, Belaunzaran-Zamudio, P, Matining, RM, Wilson, CC, Flexner, CW, Clagett, B, Plants, J, Read, S, Purdue, L, Myers, L, Boone, L, Tebas, P, Kumar, P, Clifford, D, Douek, D, Silvestri, G, Landay, AL & Lederman, MM 2016, 'The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1', AIDS Research and Human Retroviruses, vol. 32, no. 7, pp. 636-647. https://doi.org/10.1089/aid.2015.0336
Jacobson JM, Bosinger SE, Kang M, Belaunzaran-Zamudio P, Matining RM, Wilson CC et al. The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. AIDS Research and Human Retroviruses. 2016 Jul 1;32(7):636-647. https://doi.org/10.1089/aid.2015.0336
Jacobson, Jeffrey M. ; Bosinger, Steven E. ; Kang, Minhee ; Belaunzaran-Zamudio, Pablo ; Matining, Roy M. ; Wilson, Cara C. ; Flexner, Charles Williams ; Clagett, Brian ; Plants, Jill ; Read, Sarah ; Purdue, Lynette ; Myers, Laurie ; Boone, Linda ; Tebas, Pablo ; Kumar, Princy ; Clifford, David ; Douek, Daniel ; Silvestri, Guido ; Landay, Alan L. ; Lederman, Michael M. / The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. In: AIDS Research and Human Retroviruses. 2016 ; Vol. 32, No. 7. pp. 636-647.
@article{071be89aacbb487b8fd2eedfe9048970,
title = "The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1",
abstract = "Immune activation associated with HIV-1 infection contributes to morbidity and mortality. We studied whether chloroquine, through Toll-like receptor (TLR) antagonist properties, could reduce immune activation thought to be driven by TLR ligands, such as gut-derived bacterial elements and HIV-1 RNAs. AIDS Clinical Trials Group A5258 was a randomized, double-blind, placebo-controlled study in 33 HIV-1-infected participants off antiretroviral therapy (ART) and 37 participants on ART. Study participants in each cohort were randomized 1:1 to receive chloroquine 250 mg orally for the first 12 weeks then cross over to placebo for 12 weeks or placebo first and then chloroquine. Combining the periods of chloroquine use in both arms of the on-ART cohort yielded a modest reduction in the proportions of CD8 T cells co-expressing CD38 and DR (median decrease = 3.0{\%}, p = .003). The effect on immune activation in the off-ART cohort was likely confounded by increased plasma HIV-1 RNA during chloroquine administration (median 0.29 log10 increase, p <.001). Transcriptional analyses in the off-ART cohort showed decreased expression of interferon-stimulated genes in 5 of 10 chloroquine-treated participants and modest decreases in CD38 and CCR5 RNAs in all chloroquine-treated participants. Chloroquine modestly reduced immune activation in ART-treated HIV-infected participants. Clinical Trials Registry Number: NCT00819390.",
author = "Jacobson, {Jeffrey M.} and Bosinger, {Steven E.} and Minhee Kang and Pablo Belaunzaran-Zamudio and Matining, {Roy M.} and Wilson, {Cara C.} and Flexner, {Charles Williams} and Brian Clagett and Jill Plants and Sarah Read and Lynette Purdue and Laurie Myers and Linda Boone and Pablo Tebas and Princy Kumar and David Clifford and Daniel Douek and Guido Silvestri and Landay, {Alan L.} and Lederman, {Michael M.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1089/aid.2015.0336",
language = "English (US)",
volume = "32",
pages = "636--647",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1

AU - Jacobson, Jeffrey M.

AU - Bosinger, Steven E.

AU - Kang, Minhee

AU - Belaunzaran-Zamudio, Pablo

AU - Matining, Roy M.

AU - Wilson, Cara C.

AU - Flexner, Charles Williams

AU - Clagett, Brian

AU - Plants, Jill

AU - Read, Sarah

AU - Purdue, Lynette

AU - Myers, Laurie

AU - Boone, Linda

AU - Tebas, Pablo

AU - Kumar, Princy

AU - Clifford, David

AU - Douek, Daniel

AU - Silvestri, Guido

AU - Landay, Alan L.

AU - Lederman, Michael M.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Immune activation associated with HIV-1 infection contributes to morbidity and mortality. We studied whether chloroquine, through Toll-like receptor (TLR) antagonist properties, could reduce immune activation thought to be driven by TLR ligands, such as gut-derived bacterial elements and HIV-1 RNAs. AIDS Clinical Trials Group A5258 was a randomized, double-blind, placebo-controlled study in 33 HIV-1-infected participants off antiretroviral therapy (ART) and 37 participants on ART. Study participants in each cohort were randomized 1:1 to receive chloroquine 250 mg orally for the first 12 weeks then cross over to placebo for 12 weeks or placebo first and then chloroquine. Combining the periods of chloroquine use in both arms of the on-ART cohort yielded a modest reduction in the proportions of CD8 T cells co-expressing CD38 and DR (median decrease = 3.0%, p = .003). The effect on immune activation in the off-ART cohort was likely confounded by increased plasma HIV-1 RNA during chloroquine administration (median 0.29 log10 increase, p <.001). Transcriptional analyses in the off-ART cohort showed decreased expression of interferon-stimulated genes in 5 of 10 chloroquine-treated participants and modest decreases in CD38 and CCR5 RNAs in all chloroquine-treated participants. Chloroquine modestly reduced immune activation in ART-treated HIV-infected participants. Clinical Trials Registry Number: NCT00819390.

AB - Immune activation associated with HIV-1 infection contributes to morbidity and mortality. We studied whether chloroquine, through Toll-like receptor (TLR) antagonist properties, could reduce immune activation thought to be driven by TLR ligands, such as gut-derived bacterial elements and HIV-1 RNAs. AIDS Clinical Trials Group A5258 was a randomized, double-blind, placebo-controlled study in 33 HIV-1-infected participants off antiretroviral therapy (ART) and 37 participants on ART. Study participants in each cohort were randomized 1:1 to receive chloroquine 250 mg orally for the first 12 weeks then cross over to placebo for 12 weeks or placebo first and then chloroquine. Combining the periods of chloroquine use in both arms of the on-ART cohort yielded a modest reduction in the proportions of CD8 T cells co-expressing CD38 and DR (median decrease = 3.0%, p = .003). The effect on immune activation in the off-ART cohort was likely confounded by increased plasma HIV-1 RNA during chloroquine administration (median 0.29 log10 increase, p <.001). Transcriptional analyses in the off-ART cohort showed decreased expression of interferon-stimulated genes in 5 of 10 chloroquine-treated participants and modest decreases in CD38 and CCR5 RNAs in all chloroquine-treated participants. Chloroquine modestly reduced immune activation in ART-treated HIV-infected participants. Clinical Trials Registry Number: NCT00819390.

UR - http://www.scopus.com/inward/record.url?scp=84976485600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976485600&partnerID=8YFLogxK

U2 - 10.1089/aid.2015.0336

DO - 10.1089/aid.2015.0336

M3 - Article

C2 - 26935044

AN - SCOPUS:84976485600

VL - 32

SP - 636

EP - 647

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 7

ER -